Myriad Genetics (STU:MYD) Cyclically Adjusted FCF per Share: €0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:MYD Myriad Genetics Inc STU:MYD
57 GF Score
Price €5.39
GF Value €13.08
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics Cyclically Adjusted FCF per Share?

Myriad Genetics STU:MYD -0.15% 57 Cyclically Adjusted FCF per Share is €0.00 as of Mar. 2026. GuruFocus rates STU:MYD with a GF Score™ of 57/100 and a GF Value™ of €13.08 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Myriad Genetics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.205. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Myriad Genetics's average Cyclically Adjusted FCF Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -54.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -40.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Myriad Genetics was 210.70% per year. The lowest was -54.10% per year. And the median was 7.80% per year.

As of today (2026-07-20), Myriad Genetics's current stock price is €5.386. Myriad Genetics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €0.00. Myriad Genetics's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Myriad Genetics was 2987.82. The lowest was 6.29. And the median was 18.43.


Myriad Genetics  (STU:MYD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Myriad Genetics was 2987.82. The lowest was 6.29. And the median was 18.43.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Myriad Genetics Cyclically Adjusted FCF per Share Related Terms


Myriad Genetics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Myriad Genetics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics Cyclically Adjusted FCF per Share Chart

Myriad Genetics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.28 1.06 0.55 0.38 0.09

Myriad Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.20 0.17 0.09 0.00

STU:MYD vs FLGT, CSTL, BDSX: Cyclically Adjusted FCF per Share Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics Cyclically Adjusted Price-to-FCF vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Cyclically Adjusted Price-to-FCF falls into.


STU:MYD
57GF Score
Myriad Genetics Inc STU:MYD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myriad Genetics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Myriad Genetics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.205/330.2130*330.2130
=-0.205

Current CPI (Mar. 2026) = 330.2130.

Myriad Genetics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.437 241.018 0.599
201609 -0.057 241.428 -0.078
201612 0.403 241.432 0.551
201703 0.542 243.801 0.734
201706 0.458 244.955 0.617
201709 0.261 246.819 0.349
201712 0.363 246.524 0.486
201803 0.096 249.554 0.127
201806 0.541 251.989 0.709
201809 0.076 252.439 0.099
201812 0.402 251.233 0.528
201903 0.041 254.202 0.053
201906 0.356 256.143 0.459
201909 0.177 256.759 0.228
201912 -0.064 256.974 -0.082
202003 0.168 258.115 0.215
202006 0.329 257.797 0.421
202009 -0.691 260.280 -0.877
202012 -0.228 260.474 -0.289
202103 0.715 264.877 0.891
202106 -0.096 271.696 -0.117
202109 -0.441 274.310 -0.531
202112 -0.143 278.802 -0.169
202203 -0.599 287.504 -0.688
202206 -0.664 296.311 -0.740
202209 -0.257 296.808 -0.286
202212 -0.255 296.797 -0.284
202303 -0.651 301.836 -0.712
202306 -0.223 305.109 -0.241
202309 -0.453 307.789 -0.486
202312 -0.724 306.746 -0.779
202403 -0.278 312.332 -0.294
202406 -0.065 314.175 -0.068
202409 -0.056 315.301 -0.059
202412 0.007 315.605 0.007
202503 -0.249 319.799 -0.257
202506 -0.192 322.561 -0.197
202509 0.136 324.800 0.138
202512 0.042 324.054 0.043
202603 -0.205 330.213 -0.205

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.00 mean?
Myriad Genetics (STU:MYD) has a Cyclically Adjusted FCF per Share of €0.00 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Myriad Genetics and its competitors.
Is Myriad Genetics' Cyclically Adjusted FCF per Share too high?
Myriad Genetics' current Cyclically Adjusted FCF per Share is €0.00. Overall, Myriad Genetics has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Cyclically Adjusted FCF per Share compare to FLGT and CSTL?
Myriad Genetics' Cyclically Adjusted FCF per Share of €0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted FCF per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Cyclically Adjusted FCF per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.08, compared to a current price of €5.39 — trading 58.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.00. Myriad Genetics' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Cyclically Adjusted FCF per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €5.39 is trading 58.8% below its estimated GF Value™ of €13.08. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

  • Cyclically Adjusted FCF per Share: €0.00
  • GF Value™: €13.08 vs. price of €5.39 (58.8% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
57GF Score

Get the complete analysis for STU:MYD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.39
Price
€13.08
GF Value